News Release

September 26, 2019
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Assignment of Responsibilities to a Director and Personnel Change

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that assignment of responsibilities to a director and personnel change effective October 1, 2019.

1. Assignment of Responsibilities to a Director

Name	New Title	Current Title
Mamoru MORITA	Senior Executive Director, Executive Director, Sales Division	Senior Executive Director, Head of Sales Division

2. Personnel change of Corporate Officer

Name	New Title	Current Title
Yoshihiko Ohnishi	Director, Sales Division	Corporate Officer, Executive Director, Sales Division

<Reference>

Members of the Board of Directors, Audit & Supervisory Board and Corporate Officers
(October 1, 2019)

Board of internal Directors

Title	Name	Area of Supervision・ Concurrent Position
Chairman, President & CEO	Shin ASHIDA	-
Representative Director and Senior Vice President	Hiroshi YOSHIMOTO	Head of Production Division・General Manager, Production Division
Vice President	Yuji SATO, M.D., Ph.D.	Head of Research Division and Development Division
Senior Executive Director	Mamoru MORITA	Executive Director, Sales Division
Senior Executive Director	Toru ASHIDA	In charge of Corporate Strategy, Head of Quality Assurance Division, Corporate Planning Division, Administration Division and Medical Affairs Department

Corporate Officers

Title	Member
Corporate Officer, Executive Director, Administration Division	Akihiro Haguchi
Corporate Officer, Director, Overseas Business Promotion	Takayo Egawa
Corporate Officer, Executive Director, Research Division	Tohru Hirato, D.V.M.
Corporate Officer, Executive Director, Corporate Planning Division	Yutaka Honda
Corporate Officer, Executive Director, Research Planning Division	Hiroyuki Sonoda, Ph.D
Corporate Officer, Executive Director, Quality Assurance Division	Atsuko Sato

[About JCR Pharmaceuticals]

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

END

###